Scalable Osteogenic Screening Platforms: A Potential Strategy to Support Bone Regeneration in Cancer-associated Skeletal Disease

Dear Editor,

Bone metastasis is a frequent complication of advanced malignancies, particularly breast, prostate and lung cancers. Tumour colonisation of bone disrupts the physiological balance between osteoclast-mediated resorption and osteoblast-driven bone formation, leading to osteolytic, osteoblastic or mixed skeletal lesions. The metastatic bone niche involves complex interactions between tumour cells, osteoblasts, osteoclasts and stromal components that collectively promote tumour growth and skeletal destruction. Clinically, these processes manifest as skeletal-related events including pathological fractures, spinal cord compression, hypercalcaemia and severe bone pain, which substantially impair patient quality of life and survival outcomes.^1-3 The aim of this perspective is to highlight the emerging role of scalable osteogenic screening platforms as translational tools for identifying bone anabolic strategies in cancer-associated skeletal disease. In particular, this article seeks to contextualise these platforms within the tumour–bone microenvironment, emphasising their utility in systematically evaluating small-molecule modulators of osteoblast differentiation. Furthermore, we aim to underscore their potential to complement existing anti-resorptive therapies and contribute to the development of integrated approaches for preserving skeletal integrity in metastatic cancer.

Osteogenic differentiation is a tightly regulated multistep process involving lineage commitment of mesenchymal progenitor cells followed by activation of transcription factors such as Runx2 and Osterix, increased alkaline phosphatase activity, extracellular matrix synthesis and mineral deposition. Osteoblasts are also active participants in the metastatic bone microenvironment and can influence tumour behaviour through reciprocal signalling pathways that regulate bone remodelling and tumour cell survival.^4,5 These insights have stimulated interest in therapeutic strategies that enhance osteoblast-mediated bone formation in addition to suppressing osteoclast-driven bone destruction.

Recent advances in experimental systems have highlighted the value of multiparametric cell-based assays for investigating osteogenic differentiation. Such platforms integrate complementary readouts – including enzymatic activity assays, transcriptional profiling of osteogenic markers, protein-level validation and functional mineralisation measurements – to capture sequential stages of osteoblast maturation within a unified framework. When implemented in scalable formats such as 96-well screening platforms, these systems enable improved standardisation, reproducibility and parallel evaluation of candidate small-molecule modulators.

Although simplified in vitro models cannot fully reproduce the complexity of tumour–bone interactions, they provide an important early step in identifying compounds capable of enhancing osteoblast differentiation and bone formation. Candidate molecules identified through such screening approaches may subsequently be evaluated in more physiologically relevant systems incorporating tumour-conditioned environments, co-culture models or in vivo metastasis studies.⁶ Strengthening osteogenic capacity alongside inhibition of bone resorption may therefore represent a complementary therapeutic strategy for preserving skeletal integrity in metastatic cancer.

Beyond compound discovery, scalable osteogenic screening platforms may also support mechanistic investigations into signalling pathways that regulate osteoblast activity in pathological bone environments. High-content screening approaches combined with transcriptomic or proteomic analyses could enable the identification of molecular networks governing osteogenic commitment and matrix mineralisation. Such integrated strategies may help prioritise therapeutic targets capable of restoring bone homeostasis in metastatic disease. Furthermore, the adaptability of these assays to automated workflows and miniaturised formats offers potential for larger compound libraries to be evaluated efficiently. Future advancements in this field are likely to involve integration of high-content screening technologies with transcriptomic, proteomic and epigenomic profiling to enable deeper characterisation of osteogenic regulatory networks. The incorporation of artificial intelligence and machine learning approaches may further enhance data interpretation and facilitate the identification of predictive biomarkers of osteogenic response. In addition, development of more physiologically relevant models, including 3D co-culture systems and tumour–bone microenvironment simulations, may improve translational accuracy. Such advances have the potential to accelerate the discovery of targeted bone anabolic therapies and support precision medicine approaches in cancer-associated skeletal disease.

Key methodological components and representative readouts used in scalable osteogenic screening platforms are summarised in Table 1. Table 2 summarises the representative recent clinical trials relevant to bone anabolic and anti-resorptive strategies.^7-10

From a translational perspective, we recommend the systematic integration of scalable osteogenic screening platforms into early-stage drug discovery and repurposing pipelines. Such platforms can enable efficient identification and prioritisation of small-molecule modulators that enhance osteoblast differentiation and function. In addition, incorporating these assays alongside existing preclinical models may improve the evaluation of combination strategies that simultaneously suppress osteoclast-mediated bone resorption and promote bone formation. This dual approach may provide a more comprehensive framework for preserving skeletal integrity and reducing morbidity in patients with metastatic cancer.

In summary, scalable osteogenic differentiation platforms provide a useful experimental framework for systematic evaluation of small-molecule modulators of bone formation. By facilitating early-stage compound discovery and mechanistic investigation, such systems may contribute to the development of complementary strategies aimed at reducing skeletal morbidity in patients with metastatic cancer.